Literature DB >> 28226333

Prescription Opioid Abuse in Chronic Pain: An Updated Review of Opioid Abuse Predictors and Strategies to Curb Opioid Abuse: Part 1.

Alan D Kaye, Mark R Jones1, Adam M Kaye, Juan G Ripoll2, Vincent Galan3, Burton D Beakley2, Frank Calixto2, Jamie L Bolden4, Richard D Urman, Laxmaiah Manchikanti.   

Abstract

Chronic pain and prescription opioid abuse are extremely prevalent both in this country and worldwide. Consequences of opioid misuse can be life-threatening with significant morbidity and mortality, exacting a heavy toll on patients, physicians, and society. Individuals with chronic pain and co-occurring substance use disorders and/or mental health disorders, are at a higher risk for misuse of prescribed opioids. Opioid abuse and misuse occurs for a variety of reasons, including self-medication, use for reward, compulsive use because of addiction, and diversion for profit. There is a significant need for treatment approaches that balance treating chronic pain; while minimizing risks for opioid abuse, misuse, and diversion. The use of chronic opioid therapy for chronic non-cancer pain has increased dramatically in the past 2 decades in conjunction with associated increases in the abuse of prescribed opioids and accidental opioid overdoses. Consequently, a validated screening instrument which provides an effective and rational method of selecting patients for opioid therapy, predicting risk, and identifying problems once they arise could be of enormous benefit in clinical practice. Such an instrument could potentially curb the risk of iatrogenic addiction. Although several screening instruments and strategies have been introduced in recent years, there is no single test or instrument which can reliably and accurately predict those patients not suitable for opioid therapy or identify those who need increased vigilance or monitoring during therapy. At present, screening for opioid abuse includes assessment of premorbid and comorbid substance abuse; assessment of aberrant drug-related behaviors; risk factor stratification; and utilization of opioid assessment screening tools. Multiple opioid assessment screening tools and instruments have been developed by various authors. In addition, urine drug testing, monitoring of prescribing practices, prescription monitoring programs, opioid treatment agreements, and utilization of universal precautions are essential. Presently, a combination of strategies is recommended to stratify risk, to identify and understand aberrant drug related behaviors, and to tailor treatments accordingly. This manuscript builds on the 2012 opioid guidelines published in Pain Physician and the 2016 guidelines released by the Centers for Disease Control and Prevention. It reviews the current state of knowledge regarding the growing problem of opioid abuse and misuse; known risk factors; and methods of predicting, assessing, monitoring, and addressing opioid abuse and misuse in patients with chronic non-cancer pain.Key words: Opioids, misuse, abuse, chronic pain, prevalence, risk assessment, risk management, drug monitoring, aberrant drug-related behavior.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28226333

Source DB:  PubMed          Journal:  Pain Physician        ISSN: 1533-3159            Impact factor:   4.965


  65 in total

Review 1.  A Comprehensive Update on the Treatment and Management of Postdural Puncture Headache.

Authors:  Riki Patel; Ivan Urits; Vwaire Orhurhu; Mariam Salisu Orhurhu; Jacquelin Peck; Emmanuel Ohuabunwa; Andrew Sikorski; Armeen Mehrabani; Laxmaiah Manchikanti; Alan D Kaye; Rachel J Kaye; John A Helmstetter; Omar Viswanath
Journal:  Curr Pain Headache Rep       Date:  2020-04-22

2.  Negative Affect-Related Factors Have the Strongest Association with Prescription Opioid Misuse in a Cross-Sectional Cohort of Patients with Chronic Pain.

Authors:  Gadi Gilam; John A Sturgeon; Dokyoung S You; Ajay D Wasan; Beth D Darnall; Sean C Mackey
Journal:  Pain Med       Date:  2020-02-01       Impact factor: 3.750

Review 3.  Labeling Morphine Milligram Equivalents on Opioid Packaging: a Potential Patient Safety Intervention.

Authors:  Alexander B Stone; Richard D Urman; Alan D Kaye; Michael C Grant
Journal:  Curr Pain Headache Rep       Date:  2018-05-31

4.  Long-term opioid therapy definitions and predictors: A systematic review.

Authors:  Ruchir N Karmali; Christopher Bush; Sudha R Raman; Cynthia I Campbell; Asheley C Skinner; Andrew W Roberts
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-12-18       Impact factor: 2.890

5.  Sex differences in prescription opioid use patterns assessed through a community engagement program in Florida.

Authors:  Mirsada Serdarevic; Catherine W Striley; Kelly K Gurka; Robert F Leeman; Linda B Cottler
Journal:  Drug Alcohol Depend       Date:  2019-09-20       Impact factor: 4.492

6.  Spontaneous and Evoked Measures of Pain in Murine Models of Monoarticular Knee Pain.

Authors:  Hollis E Krug; Christopher Dorman; Nicole Blanshan; Sandra Frizelle; Maren Mahowald
Journal:  J Vis Exp       Date:  2019-02-22       Impact factor: 1.355

7.  Prescription Opioid Misuse in US Older Adults: Associated Comorbidities and Reduced Quality of Life in the National Epidemiologic Survey of Alcohol and Related Conditions-III.

Authors:  Ty S Schepis; Sean Esteban McCabe
Journal:  J Clin Psychiatry       Date:  2019-11-19       Impact factor: 4.384

Review 8.  Recommendations for Substance Abuse and Pain Control in Patients with Chronic Pain.

Authors:  Nalini Vadivelu; Alice M Kai; Gopal Kodumudi; Dan Haddad; Vijay Kodumudi; Niketh Kuruvilla; Alan David Kaye; Richard D Urman
Journal:  Curr Pain Headache Rep       Date:  2018-03-19

9.  Real-time associations between young adults' momentary pain and prescription opioid misuse intentions in daily life.

Authors:  Lauren M Papp; Chrystyna D Kouros; John J Curtin
Journal:  Am Psychol       Date:  2020-09

10.  CANUE: A Theoretical Model of Pain as an Antecedent for Substance Use.

Authors:  Erin Ferguson; Emily Zale; Joseph Ditre; Danielle Wesolowicz; Bethany Stennett; Michael Robinson; Jeff Boissoneault
Journal:  Ann Behav Med       Date:  2021-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.